MedPage Today on MSN4d
Daily Oral Islatravir and Doravirine Just as Effective as Other ART Regimens for HIV
Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
HIV and Syphilis Testing Just Got Faster: bioLytical Launches the 1-Minute INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in Australia
The fastest rapid dual test for HIV and syphilis is now available in Australia, expanding access to reliable and accessible screening. A Major Step Forward in Infectious Disease Screening The INSTI® ...
European Medical Journal9d
Study Highlights Long-Term Safety of T Cell Gene Therapy
A recent study on T cell gene therapy trials shows that while secondary malignancies occur in a small percentage of patients, ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Merck (NYSE:MRK) Unveils New Data On Cardiovascular Advances At ACC.25 Annual Conference
Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of ...
The Lancet10d
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
Merck says DOR/ISL met primary efficacy success criterion in two Phase 3 trials
Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...